BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 16929683)

  • 1. Structural proteomics and computational analysis of a deadly pathogen: combating Mycobacterium tuberculosis from multiple fronts.
    Strong M; Goulding CW
    Methods Biochem Anal; 2006; 49():245-69. PubMed ID: 16929683
    [No Abstract]   [Full Text] [Related]  

  • 2. Exploring functional genomics for the development of novel intervention strategies against tuberculosis.
    Rachman H; Kaufmann SH
    Int J Med Microbiol; 2007 Nov; 297(7-8):559-67. PubMed ID: 17467338
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Potential drug targets in Mycobacterium tuberculosis through metabolic pathway analysis.
    Anishetty S; Pulimi M; Pennathur G
    Comput Biol Chem; 2005 Oct; 29(5):368-78. PubMed ID: 16213791
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Lessons from molecular epidemiology and comparative genomics.
    Mathema B; Kurepina N; Fallows D; Kreiswirth BN
    Semin Respir Crit Care Med; 2008 Oct; 29(5):467-80. PubMed ID: 18810681
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pathogenicity in the tubercle bacillus: molecular and evolutionary determinants.
    Gordon SV; Bottai D; Simeone R; Stinear TP; Brosch R
    Bioessays; 2009 Apr; 31(4):378-88. PubMed ID: 19274661
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Characterization of Tunisian Mycobacterium tuberculosis rifampin-resistant clinical isolates.
    Soudani A; Hadjfredj S; Zribi M; Masmoudi A; Messaoud T; Tiouri H; Fendri C
    J Clin Microbiol; 2007 Sep; 45(9):3095-7. PubMed ID: 17652484
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Isoniazid activity is terminated by bacterial persistence.
    Mitchison DA; Jindani A; Davies GR; Sirgel F
    J Infect Dis; 2007 Jun; 195(12):1871-2; author reply 1872-3. PubMed ID: 17492605
    [No Abstract]   [Full Text] [Related]  

  • 8. Persistence, not resistance, is the cause of loss of isoniazid effect.
    Wallis RS; Palaci M; Eisenach K
    J Infect Dis; 2007 Jun; 195(12):1870-1; author reply 1872-3. PubMed ID: 17492604
    [No Abstract]   [Full Text] [Related]  

  • 9. [Development of antituberculous drugs: current status and future prospects].
    Tomioka H; Namba K
    Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921
    [TBL] [Abstract][Full Text] [Related]  

  • 10. CASTB (the comprehensive analysis server for the Mycobacterium tuberculosis complex): A publicly accessible web server for epidemiological analyses, drug-resistance prediction and phylogenetic comparison of clinical isolates.
    Iwai H; Kato-Miyazawa M; Kirikae T; Miyoshi-Akiyama T
    Tuberculosis (Edinb); 2015 Dec; 95(6):843-844. PubMed ID: 26542225
    [No Abstract]   [Full Text] [Related]  

  • 11. Drug resistance in tuberculosis.
    Ebrahim GJ
    J Trop Pediatr; 2007 Jun; 53(3):147-9. PubMed ID: 17526511
    [No Abstract]   [Full Text] [Related]  

  • 12. Tuberculosis. Few mutations divide some drug-resistant TB strains.
    Koenig R
    Science; 2007 Nov; 318(5852):901-2. PubMed ID: 17991835
    [No Abstract]   [Full Text] [Related]  

  • 13. Databases and resources for in silico proteome analysis.
    Pruess M; Kersey P; Kulikova T; Apweiler R
    Methods Biochem Anal; 2006; 49():397-414. PubMed ID: 16929689
    [No Abstract]   [Full Text] [Related]  

  • 14. [The specific features of bacterial isolation and drug resistance of Mycobacteria in extrapulmonary tuberculosis].
    Vishnevskiĭ BI; Manicheva OA; Vishnevskaia EB; Mel'nikova NN; Otten TF
    Probl Tuberk Bolezn Legk; 2006; (11):18-21. PubMed ID: 17195585
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Molecular characterisation of isoniazid-resistant Mycobacterium tuberculosis isolated from new cases in Lagunes region (Côte d'Ivoire).
    N'Guessan KR; Dosso M; Ekaza E; Kouakou J; Jarlier V
    Int J Antimicrob Agents; 2008 May; 31(5):498-500. PubMed ID: 18313272
    [No Abstract]   [Full Text] [Related]  

  • 16. Mycobacterium tuberculosis and whole genome sequencing: a practical guide and online tools available for the clinical microbiologist.
    Satta G; Atzeni A; McHugh TD
    Clin Microbiol Infect; 2017 Feb; 23(2):69-72. PubMed ID: 27642177
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Comparison of the proteomes of isoniazid-resistant Mycobacterium tuberculosis strains and isoniazid-susceptible strains].
    Jiang X; Gao F; Zhang WH; Hu ZY; Wang HH
    Zhonghua Jie He He Hu Xi Za Zhi; 2007 Jun; 30(6):427-31. PubMed ID: 17673015
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mycobacterium tuberculosis glycoproteomics based on ConA-lectin affinity capture of mannosylated proteins.
    González-Zamorano M; Mendoza-Hernández G; Xolalpa W; Parada C; Vallecillo AJ; Bigi F; Espitia C
    J Proteome Res; 2009 Feb; 8(2):721-33. PubMed ID: 19196185
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Molecular snapshot of drug-resistant and drug-susceptible Mycobacterium tuberculosis strains circulating in Bulgaria.
    Valcheva V; Mokrousov I; Narvskaya O; Rastogi N; Markova N
    Infect Genet Evol; 2008 Sep; 8(5):657-63. PubMed ID: 18657631
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Crystal structure of the Co-chaperonin Cpn10 from Thermus thermophilus HB8.
    Numoto N; Kita A; Miki K
    Proteins; 2005 Feb; 58(2):498-500. PubMed ID: 15558581
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.